NEW YORK (GenomeWeb) – Vela Diagnostics said today that it has completed the listing of its next-generation sequencing system with the US Food and Drug Administration as a class II medical device.

The diagnostic system includes the Sentosa ST401 instrument for automated template preparation and enrichment, the Sentosa SQ301 sequencer and server, and the Sentosa SQ Reporter for data analysis and report generation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.